GENESIS Ventures
VC Fund
GENESIS Ventures is an investment vehicle located in Barcelona and built up in partnership with family offices. The new fund is sized in 610.000 € and will invest in recently created Start-ups or entrepreneurial projects with a clear aim to develop innovative products through the creation of a Start-up company in the biomedical and biotechnologicalfield (therapeutics, diagnostics, medical devices and others). The investment platform is envisaged as a very early-stage tool to help the development of excellent scientific projects to reach key value milestones to attract a first round of investment from venture or corporate funds.
- Total investments:
- 7
- Last investment:
- Lead investor:
- 43%
- Fund size:
- $715k
- Last fund:
Last updated:
For AI agents: llms.txt
Industries GENESIS Ventures invests in
Stages GENESIS Ventures invests in
Countries GENESIS Ventures invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Seed
- $113k–$1.4M
Investment Focus
Industry
- Health Care 5 (71%)
- Medical 2 (29%)
- Biotechnology 2 (29%)
- Medical Device 2 (29%)
- Pharmaceutical 2 (29%)
Stage
- Seed 4 (57%)
- Funding Round 1 (14%)
- Equity Crowdfunding 1 (14%)
- Venture - Series Unknown 1 (14%)
Country
- Spain 6 (86%)
- Sweden 1 (14%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
| CEO | Total investments: 2 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Renalyse is the registered trade name of CreatSens Health S.L., a biotechnology company focusing on the development of medical platforms. | $1.1M / Oct 09, 2023 | ||
| CORIFY Care is a start-up funded by main world-wide experts on cardiac arrhythmias which is going to introduce in the market a novel medical device to non-invasively map cardiac arrhythmias in real time. This novel technology will improve the treatment in more than 10 million of atrial fibrillation patients only in Europe. Our non-invasiveelectro-anatomical mapping systems displays the activation patterns in each point of the heart without the need of invasive catheters, allowing the possibility to map all atrial fibrillation patients even during a regular visit to the cardiologist. CORIFY Care is located in Madrid, Spain, one of the most attractive places to work/live on the South of Europe. | $1.4M / Seed / Jul 07, 2021 | ||
| ABLE Human Motion is a medical device start-up based in Barcelona that was born with a clear mission: enabling mobility, for everyone. We design, develop, and will commercialize exoskeleton technology to empower every person in a wheelchair by providing greater mobility and independence. Our first product is the ABLE Exoskeleton, a wearable roboticexoskeleton that actively assists paraplegic individuals to stand up, walk and sit down. The ABLE Exoskeleton is lightweight, affordable, and easy to use, and aims to provide clinicians with a tool to increase the efficiency of rehabilitation, and users with a solution that boosts daily ambulation while empowering them in the community. | $785K / Seed / Jul 23, 2019 | ||
| MOWOOT is a Non-pharmacological & Non-invasive solution for people suffering from chronic constipation. Its solution is a wearable medical device, which provides an automatic colon-specific massage similar to the manual abdominal massage administered by health professionals.MOWOOT utilizes advanced pneumatic technology to treat and preventchronic slow transit constipation without colon cleansing supplements, enemas, and laxatives. The company emerged out of the MOEBIO dHEALTH program, which is inspired by Stanford Biodesign and Kaospilot Design and Business School from Denmark. MOWOOT was founded in 2014 and is based in Barcelona, Spain. | $456.3K / Equity Crowdfunding / Feb 05, 2019 | ||
| Quality Pharma's proprietary QS System® (“Quantum Satis”) is a powerful medical evaluation tool to accurately inform the selection of safe, quality medication-based treatment. Its unique algorithm-driven software effectively flags the potential for adverse drug events in polypharmacy, with its unparalleled ability to diagnose and revealspecific indicators (inappropriate drugs, drug duplication, drug-drug interactions, drug-disease interactions, undertreatment etc.) as well as potential adverse drug reactions in treatment programmes of multiple drugs.With modules for analysis, monitoring and evaluation, Quantum Satis traverses healthcare and brings decision support to all frontline healthcare and pharma professionals.It also provides a user-friendly interactive version for individuals, their carers and family members to complement and empower their own healthcare provision, helping ensure potential drug-related problems can be quickly identified, prevented and resolved. | $113.2K / Seed / Dec 11, 2018 | ||
|
NeuroHeal
|
NeuroHeal is a spinout from the Institut of Neurosciences from the Autonomous University of Barcelona. | $88.1K / Venture - Series Unknown / Jun 12, 2018 | |
| ADmit Therapeutics is a biotechnology company that specializes in the development of early Alzheimer's disease diagnosis tests. The company's test is based on an epigenetic analysis in blood samples, covering the analysis of a large number of methylcytosines in mtDNA by next-generation sequencing, enabling medical practitioners with aneasy way to detect early-stage Alzheimer. | Seed / Apr 01, 2018 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does GENESIS Ventures invest in?
GENESIS Ventures invests primarily in Health Care, Medical and Biotechnology startups, most often at Seed and Funding Round stage. Most of the 7 investments tracked by Shizune back companies in Spain. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What round sizes does GENESIS Ventures invest in?
GENESIS Ventures typically joins rounds of $113k–$1.4M at Seed. These are whole funding-round sizes, not GENESIS Ventures's own check, which is rarely disclosed: the 10th–90th percentile of the confirmed public funding rounds GENESIS Ventures took part in.
How do I contact GENESIS Ventures?
Public channels for GENESIS Ventures include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at GENESIS Ventures?
The team at GENESIS Ventures includes Josep Lluís Falcó (CEO). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
